Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECISION-HD2: WVE-120102 in Huntington's Disease
NCT03225846Phase 2Terminated
- Sponsor
- Wave Life Sciences
- Start
- Jul 2017
- Primary completion
- May 2021
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 8
01
Overview
A Phase 2 trial of WVE-120102 in Huntington's disease (HD), sponsored by Wave Life Sciences. Started Jul 2017; status: terminated.
02
Drugs
WVE-120102
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT03225846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03225846.